Sleep domain score improvements were statistically significant and observed throughout the twelve-month study BOSTON, June 26, 2023 /PRNewswire/ Corium, LLC, a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today that the peer-reviewed journal Frontiers in Psychiatry published an analysis of a yearlong open-label safety study of Corium's attention-deficit hyperactivity disorder (ADHD) medicine
/PRNewswire/ Corium, LLC, a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS).
/PRNewswire/ Corium LLC (Corium) announced that President and Chief Executive Officer, Perry J. Sternberg, will present at the 41st Annual J.P. Morgan.